聚糖的结构特征和低血糖效应 Polygonatum sibiricum的多糖
Xin Wang1, Mengyuan Yang1, Ying Shen1
1College of Food Engineering, Harbin University of Commerce, Heilongjiang Provincial Key Laboratory of Cereals and Comprehensive Processing of Cereal Resources, Harbin, Heilongjiang, China.
Journal of food science
|July 12, 2024
概括
在小鼠模型中,Polygonatum sibiricum多糖 (PSP) 有效抑制关键的糖尿病酶,并改善葡萄糖和脂质代谢. 这项研究支持PSP.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 自然产品 自然产品
背景情况:
- 二型糖尿病 (T2DM) 是一种全球性健康问题,其特点是胰岛素耐药性和葡萄糖代谢受损.
- 自然的多糖因其潜在的抗糖尿病特性而受到越来越多的研究.
- 聚糖 (PSP) 是一种来自P. sibiricum的有希望的候选物.
研究的目的:
- 为了描述Polygonatum sibiricum多糖体 (PSP) 的结构.
- 为了研究PSP的体外酶抑制动力学.
- 在II型糖尿病 (T2DM) 的小鼠模型中评估PSP的治疗疗效.
主要方法:
- 使用光谱和色谱技术 (例如FTIR,SEM,AFM,HPLC) 阐明PSP的结构.
- 在体外酶抑制对α-葡萄糖酶和α-氨基酶的测定.
- 评估一种链毒素诱导的T2DM小鼠模型中的代谢参数 (脂质谱,胰岛素抵抗指数,OGTT,糖化血清蛋白) 和胰腺形态.
主要成果:
- PSP具有复杂的结构,具有β-糖酸键和三环聚合.
- 在体外,PSP作为α-葡萄糖酶和α-氨基酶的可逆竞争性抑制剂.
- 在T2DM小鼠中,PSP显著改善了胰岛素敏感性,葡萄糖耐受性,脂质代谢,降低了血糖水平,同时也对肝脏和胰腺组织产生修复作用.
结论:
- 通过酶抑制和代谢改善,PSP显示出显著的抗糖尿病潜力.
- 这些发现为PSP在T2DM中的治疗作用提供了机制基础.
- PSP有望在糖尿病管理的食品和制药应用中发展.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
169
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
169
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Hypoglycemia and Glucagon
254
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
254
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
Oral Hypoglycemic Agents: Sulfonylureas
199
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
199
Oral Hypoglycemic Agents: Biguanides and Glitazones
187
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
187


